Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
GAITHERSBURG, Md., Aug. 01, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operating results following the close of U.S. financial markets on Tuesday, August 8, 2017.
Conference call details are as follows:
| Date: | Tuesday, August 8, 2017 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 15614203 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starts at 7:30 p.m. ET, August 8, 2017 until 7:30 pm ET, August 15, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 15614203 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until November 8, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
